Clinical Trials
Oncotelic Therapeutics Announces Three Abstracts on Deciparticle Everolimus Accepted for 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics will present three abstracts on its investigational intravenous Deciparticle everolimus at the 2025 San Antonio Breast Cancer Symposium, highlighting potential improvements over existing mTOR inhibitors for metastatic breast cancer treatment.
Study Finds mRNA COVID Vaccine May Enhance Cancer Immunotherapy Effectiveness
New research presented at the European Society for Medical Oncology conference suggests mRNA coronavirus vaccines could potentially boost the effectiveness of cancer immunotherapy treatments.
Oncotelic's 20nm Nanoparticle Technology Enters Human Trials for Enhanced Breast Cancer Treatment
Oncotelic Therapeutics has begun human trials for its 20nm nanoparticle formulation of Everolimus, representing a significant advancement in cancer drug delivery that could dramatically improve tumor targeting and treatment efficacy.
Oragenics Regains NYSE Compliance Following $16.5 Million Funding Round for Concussion Treatment Development
Oragenics Inc. has regained full compliance with NYSE American listing standards following a successful $16.5 million public offering, securing financial stability to advance its intranasal concussion treatment through critical clinical trials.
Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive interim Phase 2 data showing ENV-105 combined with apalutamide achieved clinical benefit in 86% of metastatic castration-resistant prostate cancer patients, potentially addressing treatment resistance in advanced disease.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
GeoVax Reports Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients
GeoVax Labs announced promising Phase 2 clinical trial results showing its multi-antigen COVID-19 vaccine candidate demonstrates strong safety and robust T-cell responses in immunocompromised patients, potentially addressing a critical gap in protection for vulnerable populations.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
Lantern Pharma Advances Rare Pediatric Brain Cancer Treatment Using AI Platform
Lantern Pharma is preparing clinical trials for a rare pediatric brain cancer treatment using its AI-powered RADR platform, following positive FDA feedback on trial design and regulatory pathways.
TransCode Therapeutics Advances Cancer Treatment with Successful Phase 1a Trial of TTX-MC138
TransCode Therapeutics has successfully completed Phase 1a clinical trials for TTX-MC138, an RNA-based cancer treatment targeting metastatic disease, showing promising safety results and disease stabilization in nearly half of patients, advancing to Phase 2 evaluation.
Soligenix Strengthens Medical Advisory Board to Advance HyBryte CTCL Treatment Through Phase 3 Development
Soligenix has updated its U.S. Medical Advisory Board with leading dermatologic and oncologic experts to guide the Phase 3 development and potential commercialization of HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma that addresses significant unmet medical needs.
Soligenix Secures $7.5 Million in Public Offering to Advance Rare Disease Pipeline Through 2026
Soligenix has closed a $7.5 million public offering that extends its financial runway through 2026, enabling continued advancement of its rare disease treatment pipeline including late-stage clinical trials and regulatory milestones.
GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
GeoVax Labs is intensifying European partnership efforts to accelerate development of vaccines for mpox, COVID-19, and cancer therapies, addressing critical global health needs.
Neutra Life Sciences Expands Clinical Research Network with New Family Medicine Partnership
Neutra Corp's subsidiary has expanded its clinical trial site network through a joint venture with MediNet Family Care Clinic, strengthening its position in community-based research for chronic conditions while enhancing investor communication.
Lifordi Immunotherapeutics Reports Promising Preclinical Data for Autoimmune Treatment LFD-200
Lifordi Immunotherapeutics will present new preclinical data showing its antibody drug conjugate LFD-200 delivers glucocorticoids directly to immune cells with sustained anti-inflammatory effects and no systemic toxicity, potentially offering a safer treatment option for autoimmune diseases.
Soligenix Expands European Medical Advisory Board to Advance CTCL Treatment Development
Soligenix is strengthening its European medical advisory board and advancing Phase 3 clinical trials for HyBryte, a potential new treatment for cutaneous T-cell lymphoma that addresses significant unmet medical needs in European patients.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
GeoVax to Present COVID-19 Vaccine Data for Immunocompromised Patients at European Vaccine Congress
GeoVax Labs will present interim safety data and special-population insights for its GEO-CM04S1 COVID-19 vaccine at the World Vaccine Congress Europe 2025, highlighting progress in addressing vaccine needs for immunocompromised patients where current options remain insufficient.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.
Soligenix's HyBryte Therapy Shows Positive Safety Profile in Phase 3 CTCL Trial
Soligenix's HyBryte therapy demonstrated a positive safety profile in its ongoing Phase 3 FLASH2 study for cutaneous T-cell lymphoma, maintaining progress toward potential regulatory approval and commercialization as a first-line treatment option.
Stanford Study Shows Pulsed Shortwave Therapy Provides Sustained Pain Relief for Thumb Arthritis
A Stanford University clinical trial demonstrates that pulsed shortwave therapy offers lasting pain relief for thumb arthritis, potentially providing a safe, drug-free alternative to current limited treatment options for millions of affected adults.
Northwest Battle Buddies to Celebrate 300th Service Dog Team as Study Confirms PTSD Treatment Benefits
Northwest Battle Buddies' milestone of pairing 300 service dogs with combat veterans comes as a landmark study validates the significant therapeutic impact these dogs provide in reducing PTSD symptoms and improving veterans' quality of life.
NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.
DGE to Host 5th Investigator-Initiated Trials Summit in Philadelphia, Addressing Clinical Research Challenges
The upcoming 5th Investigator-Initiated Trials Summit in Philadelphia brings together life sciences professionals to address critical challenges in clinical research programs, highlighting the importance of collaborative solutions in advancing medical innovation.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Sapu Nano Receives Australian Ethics Approval for Breast Cancer Drug Trial
Sapu Nano's Sapu003, an injectable form of Everolimus using proprietary nanoparticle technology, has received HREC approval for human clinical trials in Australia, potentially offering more effective breast cancer treatment through improved drug delivery.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.